Home » Stocks » VERU

Veru Inc. (VERU)

Stock Price: $3.08 USD 0.00 (0.00%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $3.06 -0.02 (-0.65%) Nov 27, 2:48 PM

Stock Price Chart

Key Info

Market Cap 214.83M
Revenue (ttm) 39.57M
Net Income (ttm) -10.20M
Shares Out 69.86M
EPS (ttm) -0.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $3.08
Previous Close $3.08
Change ($) 0.00
Change (%) 0.00%
Day's Open 3.05
Day's Range 2.95 - 3.08
Day's Volume 131,415
52-Week Range 2.17 - 4.58

More Stats

Market Cap 214.83M
Enterprise Value 207.27M
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 69.86M
Float n/a
EPS (basic) -0.16
EPS (diluted) -0.16
FCF / Share -0.04
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.17M
Short Ratio 4.82
Short % of Float n/a
Beta 0.17
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 5.43
PB Ratio 5.11
Revenue 39.57M
Operating Income -4.93M
Net Income -10.20M
Free Cash Flow -2.65M
Net Cash 7.56M
Net Cash / Share 0.11
Gross Margin 54.73%
Operating Margin -12.47%
Profit Margin -25.80%
FCF Margin -6.70%
ROA -5.18%
ROE -26.84%
ROIC -37.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(176.42% upside)
Current: $3.08
Target: 8.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth100.47%16.18%-38.29%-32.13%33.13%-22.15%-10.21%88.71%-16.46%-
Gross Profit21.668.777.0213.3518.9713.1217.5020.629.8712.92
Operating Income-6.44-16.89-8.493.026.623.929.7910.943.304.35
Net Income-12.02-23.94-6.610.344.352.4314.3415.305.406.74
Shares Outstanding63.3253.8634.6428.6728.5328.5228.3827.6927.2926.98
Earnings Per Share-0.19-0.44-
EPS Growth----93.33%87.5%-84%-5.66%178.95%-20.83%-
Dividend Per Share-----
Dividend Growth-----5%-9.09%10%33.33%-
Operating Cash Flow-5.49-11.550.98-1.71-1.553.6711.7910.366.973.99
Capital Expenditures-0.11-0.05-0.13-0.01-0.14-0.10-0.30-0.72-0.05-0.05
Free Cash Flow-5.59-11.600.85-1.72-1.683.5711.499.646.923.94
Cash & Equivalents6.303.763.282.394.115.808.925.304.322.92
Total Debt8.279.39-------0.01
Net Cash / Debt-1.98-5.633.282.394.115.808.925.304.322.91
Book Value32.3329.4848.4533.9333.1328.0731.4024.2216.7516.13
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Veru Inc.
Country United States
Employees 386
CEO Mitchell Shuster Steiner

Stock Information

Ticker Symbol VERU
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VERU
IPO Date July 19, 1990


Veru, an oncology and urology biopharmaceutical company, engages in developing novel medicines for prostate cancer treatment and prostate cancer supportive care. The company's oncology drug candidates include VERU-111, an oral alpha and beta tubulin inhibitor, which is in a development Phase 1b/2 for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a Phase 2 clinical trial for the treatment of hot flashes in men undergoing androgen deprivation therapies; and VERU-100, a GnRH antagonist that is in planned Phase 2 clinical trial for the palliative treatment of advanced prostate cancer. Its urology specialty drug candidates are TADFIN, a tadalafil and finasteride combination of tablets and capsules for the treatment of men with lower urinary tract symptoms; and Tamsulosin XR capsules, which are tamsulosin capsules for treating benign prostatic hyperplasia. The company's commercial products include the FC2 Female/Internal condoms for the prevention of pregnancy and sexually transmitted infections; and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation. Its customers primarily include international agencies, government health agencies, ministries of health, and other governmental agencies, which purchase and distribute FC2 for use in HIV/AIDS prevention and family planning programs; and telemedicine providers who sell into the prescription channel in the United States. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. is headquartered in Miami, Florida.